Abstract: The application discloses methods and compositions for inhibiting functions associated with vascular endothelial growth factor-A (VEGF-A). The methods and compositions may involve the use of pan-variant specific aptamers for binding to VEGF-A, and preventing or reducing association of VEGF-A with Flt-1, KDR, or Nrp-1. The methods and compositions may include one or more aptamers that bind to receptor binding face of VEGF-A. The methods and compositions may include one or more aptamers that bind to a receptor binding domain of VEGF-A. The application further provides anti-VEGF-A aptamers for the treatment of ocular diseases or disorders. In some cases, the anti-VEGF-A aptamers may have a stem-loop secondary structure.
Type:
Application
Filed:
January 10, 2020
Publication date:
March 31, 2022
Applicants:
DRIVE THERAPEUTICS LLC, ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Inventors:
Carl ERICKSON, Christopher P. RUSCONI, Matthew LEVY, Keith E. MAIER, Sarah E. THACKER, Derek PARKS